Evidence map›Paper›PMID 31959116›Full record

ArticleBMC microbiology2020

Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study.

Chika K Onwuamah, Jonathan Okpokwu, Rosemary Audu, Godwin Imade, Seema T Meloni, Azuka Okwuraiwe, Philippe Chebu, Adesola Z Musa, Beth Chaplin, Ibrahim Dalhatu and 12 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Chika K OnwuamahMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria. chikaonwuamah@yahoo.com.ORCID 0000-0002-5111-1822
Jonathan OkpokwuJos University Teaching Hospital, Jos, Plateau State, Nigeria.
Rosemary AuduMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
Godwin ImadeJos University Teaching Hospital, Jos, Plateau State, Nigeria.
Seema T MeloniHarvard T. H. Chan School of Public Health, Boston, MA, USA.
Azuka OkwuraiweMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
Philippe ChebuAPIN Public Health Initiative Nigeria, Ltd./Gte, Abuja, FCT, Nigeria.
Adesola Z MusaMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
Beth ChaplinHarvard T. H. Chan School of Public Health, Boston, MA, USA.
Ibrahim DalhatuCenters for Disease Control-Nigeria, Abuja, FCT, Nigeria.
Oche AgbajiJos University Teaching Hospital, Jos, Plateau State, Nigeria.
Jay SamuelsAPIN Public Health Initiative Nigeria, Ltd./Gte, Abuja, FCT, Nigeria.
Oliver EzechiMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
Mukhtar AhmedCenters for Disease Control-Nigeria, Abuja, FCT, Nigeria.
Georgina OdaiboUniversity of Ibadan, Ibadan, Oyo State, Nigeria.
David O OlaleyeUniversity of Ibadan, Ibadan, Oyo State, Nigeria.
Prosper OkonkwoAPIN Public Health Initiative Nigeria, Ltd./Gte, Abuja, FCT, Nigeria.
Babatunde Lawal SalakoMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
Elliot RaizesCenters for Disease Control and Prevention, Atlanta, GA, USA.
Chunfu YangCenters for Disease Control and Prevention, Atlanta, GA, USA.
Phyllis J KankiHarvard T. H. Chan School of Public Health, Boston, MA, USA.
Emmanuel O IdigbeMicrobiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
Nigerian Institute of Medical Research · NGAIDS Prevention Initiative in Nigeria · NGHarvard University · USJos University Teaching Hospital · NGCenters for Disease Control and Prevention · USNigeria Centre for Disease Control · NGUniversity of Ibadan · NG

Funding

ACL HHS U01GH000770CGH CDC HHS U01 GH000770PEPFARUS Centres for Disease Control and Prevention U2G GH000770
6 · The paper itself

Abstract

backgroundWe identified a HIV-positive cohort in virologic failure (VF) who re-suppressed without drug switch. We characterized their drug resistance mutations (DRM) and adherence profiles to learn how to better manage HIV drug resistance. A retrospective cohort study utilizing clinical data and stored samples. Patients received ART at three Nigerian treatment centres. Plasma samples stored when they were in VF were genotyped.

resultOf 126 patients with samples available, 57 were successfully genotyped. From ART initiation, the proportion of patients with adherence ≥90% increased steadily from 54% at first high viral load (VL) to 67% at confirmed VF, and 81% at time of re-suppressed VL. Sixteen (28%) patients had at least one DRM. Forty-six (81%) patients had full susceptibility to the three drugs in their first-line (1 L) regimen. Thirteen (23%) were resistant to at least one antiretroviral drug but three were resistant to drugs not used in Nigeria. Ten patients had resistance to their 1 L drug(s) and six were fully susceptible to the three drugs in the recommended second-line regimen.

conclusionThis cohort had little drug resistance mutations. We conclude that if adherence is not assured, patients could exhibit virologic failure without having developed mutations associated with drug resistance.

Indexed as

Drug Resistance, ViralMutationAdultAnti-HIV AgentsFemaleGenotypeHIV-1HIV InfectionsHumansMaleNigeriaPatient ComplianceRetrospective StudiesViral LoadAnti-HIV AgentsAdherenceDrug resistance mutationRe-suppressionVirologic failure

Identifiers

PMID31959116
PMCPMC6971913
OpenAlexW3001289231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.